Key features and details
- Rabbit polyclonal to SLITRK4
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Product nameAnti-SLITRK4 antibody
See all SLITRK4 primary antibodies
DescriptionRabbit polyclonal to SLITRK4
Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
Species reactivityReacts with: Mouse, Rat, Human
A 13 amino acid peptide from near the C-terminus of Human SLITRK4.
- Brain tissue lysate
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab67315 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 20 µg/ml.|
|WB||Use a concentration of 0.5 - 1 µg/ml. Detects a band of approximately 94 kDa (predicted molecular weight: 94 kDa).|
|IHC-P||Use at an assay dependent concentration.|
FunctionSuppresses neurite outgrowth.
Tissue specificityExpressed in the cerebral cortex of the brain and at higher levels in some astrocytic brain tumors such as astrocytomas, glioblastomas and primitive neuroectodermal tumors.
Sequence similaritiesBelongs to the SLITRK family.
Contains 12 LRR (leucine-rich) repeats.
Contains 2 LRRCT domains.
Contains 1 LRRNT domain.
- Information by UniProt
- DKFZp547M2010 antibody
- SLIK4_HUMAN antibody
- SLIT and NTRK like family member 4 antibody
Immunofluorescence of SLITRK4 in Human brain tissue ab67315 at 20 ug/mL.
Immunohistochemistry of Human brain tissue using ab67315 at 2.5 μg/ml.
Lane 1 : Anti-SLITRK4 antibody (ab67315) at 0.5 µg/ml
Lane 2 : Anti-SLITRK4 antibody (ab67315) at 1 µg/ml
All lanes : mouse brain tissue lysate
Lysates/proteins at 15 µg per lane.
Predicted band size: 94 kDa
Observed band size: 94 kDa
Additional bands at: 120 kDa. We are unsure as to the identity of these extra bands.
ab67315 has not yet been referenced specifically in any publications.